Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Sep;4(5):515–518. doi: 10.1128/cdli.4.5.515-518.1997

Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.

P C Woo 1, C Y Lo 1, S K Lo 1, H Siau 1, J S Peiris 1, S S Wong 1, W K Luk 1, T M Chan 1, W W Lim 1, K Y Yuen 1
PMCID: PMC170584  PMID: 9302197

Abstract

A prospective study of the spectrum of glycoprotein B (gB) and glycoprotein H (gH) genotypes of cytomegalovirus (CMV) was conducted with five categories of patients: viremic bone marrow-transplant (BMT) recipients who developed CMV disease after BMT (n = 22), viremic BMT recipients without CMV disease (n = 11), viremic renal-transplant recipients who developed CMV disease after transplantation (n = 14), viremic renal-transplant recipients without CMV disease (n = 13), and premature babies with asymptomatic congenital CMV infections (n = 13). Genotypic stability was observed because the gB and gH genotypes of multiple isolates obtained from a single patient were identical. The distribution of gH genotypes in patients of all groups studied were similar. However, there was a unique distribution of the gB genotype in the first category of patients, i.e., BMT recipients with CMV disease, which was distinct from those of all other categories (P < 0.05). CMV isolates from 54% of BMT recipients with CMV disease exhibited gB type 2, while isolates from 46, 50, 69, and 77% of the BMT recipients without CMV disease, renal-transplant recipients with and those without CMV disease, and premature babies with congenital CMV infection, respectively, were of gB type 1. An analysis of the clinical characteristics of BMT recipients with CMV disease indicated that all underwent either an allogeneic or matched, unrelated donor transplant, and half had severe acute graft-versus-host disease (grades 2 to 4). The statistically significant genotypic difference between CMV isolates from BMT recipients with and without CMV disease was not observed between isolates from renal-transplant recipients with and without CMV disease. We speculate that differences in pathogenesis in different patient groups might account for these observations. These findings would also facilitate decision making about the choice of recombinant CMV glycoprotein vaccine required to immunize transplant donors and the subsequent adoptive transfer of immunity to BMT recipients. When the source of CMV DNA required for genotyping was investigated among renal-transplant recipients, direct use of peripheral blood leukocytes was 95% effective compared to the effectiveness of cells obtained from conventional culture of peripheral blood specimens.

Full Text

The Full Text of this article is available as a PDF (1,006.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler S. P., Starr S. E., Plotkin S. A., Hempfling S. H., Buis J., Manning M. L., Best A. M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995 Jan;171(1):26–32. doi: 10.1093/infdis/171.1.26. [DOI] [PubMed] [Google Scholar]
  2. Blacklock H. A., Griffiths P., Stirk P., Prentice H. G. Specific hyperimmune globulin for cytomegalovirus pneumonitis. Lancet. 1985 Jul 20;2(8447):152–153. doi: 10.1016/s0140-6736(85)90252-1. [DOI] [PubMed] [Google Scholar]
  3. Chou S. W., Dennison K. M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis. 1991 Jun;163(6):1229–1234. doi: 10.1093/infdis/163.6.1229. [DOI] [PubMed] [Google Scholar]
  4. Chou S. Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J Infect Dis. 1992 Sep;166(3):604–607. doi: 10.1093/infdis/166.3.604. [DOI] [PubMed] [Google Scholar]
  5. Fries B. C., Chou S., Boeckh M., Torok-Storb B. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis. 1994 Apr;169(4):769–774. doi: 10.1093/infdis/169.4.769. [DOI] [PubMed] [Google Scholar]
  6. Grundy J. E., Shanley J. D., Griffiths P. D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. 1987 Oct 31;2(8566):996–999. doi: 10.1016/s0140-6736(87)92560-8. [DOI] [PubMed] [Google Scholar]
  7. Meyers J. D., Flournoy N., Thomas E. D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986 Mar;153(3):478–488. doi: 10.1093/infdis/153.3.478. [DOI] [PubMed] [Google Scholar]
  8. Miller W., Flynn P., McCullough J., Balfour H. H., Jr, Goldman A., Haake R., McGlave P., Ramsay N., Kersey J. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986 Apr;67(4):1162–1167. [PubMed] [Google Scholar]
  9. Rasmussen L. Immune response to human cytomegalovirus infection. Curr Top Microbiol Immunol. 1990;154:221–254. doi: 10.1007/978-3-642-74980-3_9. [DOI] [PubMed] [Google Scholar]
  10. Shepp D. H., Dandliker P. S., de Miranda P., Burnette T. C., Cederberg D. M., Kirk L. E., Meyers J. D. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 Sep;103(3):368–373. doi: 10.7326/0003-4819-103-3-368. [DOI] [PubMed] [Google Scholar]
  11. Shepp D. H., Match M. E., Ashraf A. B., Lipson S. M., Millan C., Pergolizzi R. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. J Infect Dis. 1996 Jul;174(1):184–187. doi: 10.1093/infdis/174.1.184. [DOI] [PubMed] [Google Scholar]
  12. Shouval D., Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. Intervirology. 1995;38(1-2):41–46. doi: 10.1159/000150413. [DOI] [PubMed] [Google Scholar]
  13. The T. H., van der Ploeg M., van den Berg A. P., Vlieger A. M., van der Giessen M., van Son W. J. Direct detection of cytomegalovirus in peripheral blood leukocytes--a review of the antigenemia assay and polymerase chain reaction. Transplantation. 1992 Aug;54(2):193–198. doi: 10.1097/00007890-199208000-00001. [DOI] [PubMed] [Google Scholar]
  14. Walter E. A., Greenberg P. D., Gilbert M. J., Finch R. J., Watanabe K. S., Thomas E. D., Riddell S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19;333(16):1038–1044. doi: 10.1056/NEJM199510193331603. [DOI] [PubMed] [Google Scholar]
  15. Winston D. J., Huang E. S., Miller M. J., Lin C. H., Ho W. G., Gale R. P., Champlin R. E. Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med. 1985 Jan;102(1):16–20. doi: 10.7326/0003-4819-102-1-16. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES